What the rules actually say.
The regulatory landscape for research peptides is moving fast. This page tracks the key FDA actions — enforcement letters, rulemaking decisions, and upcoming committee meetings — so you have the factual picture in one place. Neutral, sourced, and updated as events land.
Informational only. Not legal or medical advice. For guidance on your specific situation, consult a licensed attorney or clinician.
Where each peptide stands
Every peptide in the Merit Verified catalog, placed in its current FDA regulatory bucket. Tap any peptide to see its full evidence profile.
Full FDA approval for human use. Legal with a valid prescription.
In FDA-regulated clinical trials. Not yet approved for general use.
Currently restricted from 503A compounding (significant safety concerns). FDA committee meets July 2026 to reconsider.
No FDA evaluation for compounding. Sold as "research use only." Gray-market status.
Reviewed June 7, 2026 · Classifications sourced from FDA.gov · This page rebuilds nightly
Status today
Most research peptides — including BPC-157, TB-500, and GHK-Cu — are not FDA-approved and are not legal for human use outside of a licensed compounding pharmacy or investigational new drug (IND) framework. Vendors commonly label products "research use only," but the FDA has explicitly stated it does not consider that framing a legal shield. Enforcement is active and increasing: the agency issued 80+ warning letters between September 2025 and March 2026. A PCAC meeting in July 2026 may ease compounding restrictions for select peptides — the outcome will determine whether some demand moves into a more regulated channel.
Last reviewed: June 7, 2026 · Informational only — not legal or medical advice.
Timeline
Reverse-chronological. Every item links to its primary source.
- Upcoming
PCAC meeting may return BPC-157, TB-500, and others to compounding bulks list
The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to weigh returning BPC-157, TB-500, MOTS-c, KPV, and Semax to the 503A bulk substances list. If approved, some demand would shift to licensed compounding pharmacies — a meaningful change for vendors currently operating in the gray market. The meeting is driven in part by MAHA-era regulatory easing pressure.
PBS NewsHour - Enforcement
FDA sends 30 additional warning letters; names BPC-157 alongside GLP-1s and SARMs
On March 3, 2026, the FDA issued 30 more warning letters to telehealth and direct-to-consumer companies. The agency explicitly stated it views "research use only" labeling as a ruse — not a legal shield — and named BPC-157 in the same enforcement context as GLP-1 compounds and SARMs. This followed a September 2025 wave and signals sustained, escalating enforcement.
FDA.gov - Enforcement
FDA issues 50+ warning letters in direct-to-consumer peptide crackdown
The FDA sent more than 50 warning letters to companies marketing compounded peptides directly to consumers. The action targeted vendors and telehealth platforms selling BPC-157, TB-500, and related compounds outside the approved-drug framework, often without a valid prescription or adequate labeling disclosures.
FDA.gov - Rulemaking
FDA places ~19 peptides on Category 2 "significant safety concerns" list
The FDA moved approximately 19 peptides to a Category 2 designation, citing significant safety concerns including potential cancer, liver, kidney, and cardiovascular risks. Most popular research peptides — including BPC-157 — remained available only through 503A compounding pharmacies and were not FDA-approved for human use. This classification hardened the regulatory framework these peptides operate under.
FDA.gov
Merit Verified publishes this tracker as a factual reference for researchers and buyers trying to understand the regulatory environment. It is not legal advice, medical advice, or a compliance guide. Rules and enforcement posture change — check primary sources for the most current information. The existing "research use only" disclaimer on Merit Verified applies in full to all content on this page.